Shah Capital pushes for Novavax (NVAX) sale

Shah Capital is urging Novavax (NASDAQ: NVAX) board to pursue a sale, according to a Reuters report on Tuesday.

• The fund is citing a third consecutive year of poor roll-out of its COVID-19 shot.
• Shah Capital owns a 7.2% stake in the company and is the second largest shareholders.

You May Also Be Interested In

• People Incorporated withdraws bid to acquire MGM Resorts
• OceanaGold CEO Gerard Bond to retire in April 2027
• First Merchants prices $100M subordinated notes offering at 6.75%